The blood-brain barrier (BBB) is a critical determinant of central nervous system (CNS) drug transport, safety, and efficacy. Conventional models often fail to capture its complexity, leading to translational gaps. SynVivo’s SynBBB™ platform recreates physiologically relevant, vascularized microfluidic channels digitized from real microvasculature, enabling dynamic studies of drug transport under flow.
To enhance assay consistency and predictive reliability, SynVivo and KOLAIDO have developed an AI/ML-driven quality assessment pipeline. Using phase contrast imaging and the IKOSA platform, the model automatically detects subtle patterns in the vascularized channel and classifies them as good, acceptable, or bad. The approach not only improves experimental reproducibility but also allows non-invasive, label-free monitoring of barrier disruption post-dosing.
By combining advanced microfluidic modeling with intelligent automation, SynBBB™ sets a new standard for reproducible, human-relevant BBB research, accelerating CNS drug discovery while minimizing experimental variability and reducing reliance on animal testing.
